Benito-Villalvilla C, de la Rocha-Munoz A, Lopez-Abente J, Eggel A, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-alpha production and FOXP3(+) Treg generation. Allergy 2023;78:1060-1072.
PMID: 36315052